Update on the use of Trandolapril in the management of cardiovascular disorders

Abstract

Abstract:Trandolapril is a well known angiotensin converting enzyme (ACE) inhibitor with many cardiovascular (CV) indications. The objectives of this article are to review the pharmacokinetics and pharmacodynamics properties of trandolapril and to focus on its clinical relevance in cardiovascular medicine. Various populations have been studied in large clinical trials including patients with congestive heart failure (CHF) after an acute myocardial infarction (AMI), diabetics, patients with hypertension (HTN), stable coronary artery disease (CAD) and prevention of proteinuria. Long-term treatment with trandolapril in patients with reduced left ventricular function soon after AMI signifi cantly reduced the risk of overall mortality, mortality from CV causes, sudden death, and the development of severe CHF. Treatment with trandolapril after AMI complicated by left ventricular dysfunction appears to be of considerable importance in patients with diabetes mellitus by saving lives and substantially reducing the risk of progression to severe CHF as well. Moreover, trandolapril reduces progression to proteinuria in high-risk patients. Some of the advantages of trandolapril over other ACE inhibitors are the wide spectrum of patient populations studied, the well established dosage and its proven trough-to-peak effect ratios permitting a safe once-a-day administration.

Effects of Trandolapril on Structural, Contractile and Electrophysiological Remodeling in Experimental Volume Overload Heart Failure

“…due to myocardial infarction, trandolapril decreased the mortality rate, incidence of atrial fibrillation, risk of sudden death, and development of severe heart failure (Diaz and Ducharme, 2008). Similar to clinical studies, multiple vascular and cardiac effects of trandolapril were also demonstrated in animal models (Fornes et al, 1992;Koffi et al, 1998;Tanonaka et al, 2001).…”

In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine

“…Since decreasing blood pressure is vital in lowering the risk of developing cardiovascular problems in patients with type 2 diabetes mellitus, a combination of anti-diabetic and anti-hypertension drugs is required and widely employed (Sharma et al, 2007). In vitro and clinical research studies have shown that verapamil inhibits P-gp (Nies et al, 2011;Uchida et al, 2014).…”